Cited by 318Glioma Diagnosis and TreatmentAdvanced MRI Techniques and ApplicationsMetabolomics and Mass Spectrometry Studies

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy

Open access

Pope, Whitney B., Prins, Robert M., Albert Thomas, M., Nagarajan, Rajakumar, Yen, Katharine E., Bittinger, Mark A., Salamon, Noriko, Chou, Arthur P., Yong, William H., Soto, Horacio, Wilson, Neil, Driggers, Edward, Jang, Hyun G., Su, Shinsan M., Schenkein, David P., Lai, Albert, Cloughesy, Timothy F., Kornblum, Harley I., Wu, Hong, Fantin, Valeria R., Liau, Linda M.·2012·Journal of Neuro-Oncology

DOI 10.1007/s11060-011-0737-8PMC PMC3650613

Open this paper in CoChat — free account

Abstract

Mutations of the isocitrate dehydrogenase 1 and 2 genes (IDH1 and IDH2) are commonly found in primary brain cancers. We previously reported that a novel enzymatic activity of these mutations results in the production of the putative oncometabolite, R(-)-2-hydroxyglutarate (2-HG). Here we investigated the ability of magnetic resonance spectroscopy (MRS) to detect 2-HG production in order to non-invasively identify patients with IDH1 mutant brain tumors. Patients with intrinsic glial brain tumors (n = 27) underwent structural and spectroscopic magnetic resonance imaging prior to surgery. 2-HG levels from MRS data were quantified using LC-Model software, based upon a simulated spectrum obtained from a GAMMA library added to the existing prior knowledge database. The resected tumors were then analyzed for IDH1 mutational status by genomic DNA sequencing, Ki-67 proliferation index by immunohistochemistry, and concentrations of 2-HG and other metabolites by liquid chromatography-mass spectrometry (LC-MS). MRS detected elevated 2-HG levels in gliomas with IDH1 mutations compared to those with wild-type IDH1 (P = 0.003). The 2-HG levels measured in vivo with MRS were significantly correlated with those measured ex vivo from the corresponding tumor samples using LC-MS (r (2) = 0.56; P = 0.0001). Compared with wild-type tumors, those with IDH1 mutations had elevated choline (P = 0.01) and decreased glutathione (P = 0.03) on MRS. Among the IDH1 mutated gliomas, quantitative 2-HG values were correlated with the Ki-67 proliferation index of the tumors (r ( 2 ) = 0.59; P = 0.026). In conclusion, water-suppressed proton ((1)H) MRS provides a non-invasive measure of 2-HG in gliomas, and may serve as a potential biomarker for patients with IDH1 mutant brain tumors. In addition to 2-HG, alterations in several other metabolites measured by MRS correlate with IDH1 mutation status.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s11060-011-0737-8

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citation
Estimation of metabolite concentrations from localized in vivo proton NMR spectra
Provencher, S. W. (1993) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910300604 · Cited by 3,659
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer
WISEMAN, H., & HALLIWELL, B. (1996) · Biochemical Journal · doi:10.1042/bj3130017 · Cited by 2,345
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
Self-citation
Spatial Localization in NMR Spectroscopy in Vivo
Bottomley, P. A. (1987) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1987.tb32915.x · Cited by 1,382
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
Hartmann, C. J., Meyer, J., Balß, J., Capper, D., Mueller, W. C., Christians, A., Felsberg, J., Wolter, M., Mawrin, C., Wick, W., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0561-9 · Cited by 1,163

Show all 32 references

Research works printed but not linked: 1

Ducray F, Marie Y, Sanson M (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(21):2248 author reply 9 · DOI

Sorted by citations

Items 201–300 of 318

Chromatographic methods coupled to mass spectrometry for the determination of oncometabolites in biological samples-A review
Asensio, A. F., Álvarez-González, E., Rodríguez, A., Sierra, L. M., & Blanco‐González, E. (2021) · Analytica Chimica Acta · doi:10.1016/j.aca.2021.338646 · Cited by 10
In vitro visualization and characterization of wild type and mutant IDH homo- and heterodimers using Bimolecular Fluorescence Complementation
Robinson, G. L., Philip, B., Guthrie, M. R., Cox, J. E., Robinson, J., VanBrocklin, M. W., & Holmen, S. L. (2016) · Cancer Research Frontiers · doi:10.17980/2016.311 · Cited by 10
Astrocytic and Oligodendroglial Tumors
Brat, D. J., & Perry, A. (2010) · Elsevier eBooks · doi:10.1016/b978-0-443-06982-6.00005-5 · Cited by 10
Absolute quantification of 2‐hydroxyglutarate on tissue by matrix‐assisted laser desorption/ionization mass spectrometry imaging for rapid and precise identification of isocitrate dehydrogenase mutations in human glioma
Lan, C., Li, H., Wang, L., Zhang, J., Wang, X., Zhang, R., Yuan, X., Wu, T., Wu, J., Lu, M., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33729 · Cited by 8
Prediction of metabolites associated with somatic mutations in cancers by using genome-scale metabolic models and mutation data
Lee, G., Lee, S. M., Lee, S., Jeong, C. W., Song, H., Lee, S. Y., Yun, H., Koh, Y., & Kim, H. U. (2024) · Genome biology · doi:10.1186/s13059-024-03208-8 · Cited by 9
Microfluidics for rapid detection of isocitrate dehydrogenase 1 mutation for intraoperative application
Aibaidula, A., Zhao, W., Wu, J., Chen, H., Shi, Z., Zheng, L., Mao, Y. Q., Zhou, L., & Sui, G. (2015) · Journal of neurosurgery · doi:10.3171/2015.4.jns141833 · Cited by 9
Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms
Babakoohi, S., Lapidus, R. G., Faramand, R. G., Sausville, E. A., & Emadi, A. (2016) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000342 · Cited by 9
Advances in Molecular Imaging for Surgery
Olubiyi, O. I., Lu, F., Calligaris, D., Jolesz, F. A., & Agar, N. Y. R. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800870-6.00017-0 · Cited by 9
Precision oncology in the era of radiogenomics: the case of D-2HG as an imaging biomarker for mutant IDH gliomas
Andronesi, O. C. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy085 · Cited by 9
Neuroimaging
Pope, W. B., Djoukhadar, I., & Jackson, A. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802997-8.00003-7 · Cited by 9
Self-citation
Magnetic resonance diffusion-tensor imaging metrics in High Grade Gliomas: Correlation with IDH1 gene status in WHO 2016 era
Augelli, R., Ciceri, E. F. M., Ghimenton, C., Zoccatelli, G., Bucci, A., Nicolato, A., Beltramello, A., Pinna, G., & Ricciardi, G. K. (2019) · European Journal of Radiology · doi:10.1016/j.ejrad.2019.04.020 · Cited by 9
Spectral Analysis Based on Hemodynamic Habitat Imaging Predicts Isocitrate Dehydrogenase Status and Prognosis in High-Grade Glioma
Qiao, J., Wu, H., Liu, J., Kang, H., Wang, S., Fang, J., Zhang, J., & Zhang, W. (2023) · World Neurosurgery · doi:10.1016/j.wneu.2023.03.136 · Cited by 8
Self-citation
The Role of Advanced Brain Tumor Imaging in the Care of Patients with Central Nervous System Malignancies
Ly, I., & Gerstner, E. R. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0558-5 · Cited by 9
Imaging in Neuro-Oncology
Minniti, G. C., Romano, A., Scaringi, C., & Bozzao, A. (2019) · Springer eBooks · doi:10.1007/978-3-319-95684-8_5 · Cited by 8
Metabolic Fluxes in Cancer Metabolism
Günther, U. L., Chong, M., Volpari, T., Koczula, K. M., Atkins, K. L., Bunce, C. M., & Khanim, F. L. (2015) · Springer eBooks · doi:10.1007/978-3-7091-1824-5_14 · Cited by 8
Commentary: Pitfalls in the Neuroimaging of Glioblastoma in the Era of Antiangiogenic and Immuno/Targeted Therapy
Skolnik, A. D., Wang, S., Gopal, P. P., & Mohan, S. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00051 · Cited by 8
Detection of 2-Hydroxyglutarate by 3.0-Tesla Magnetic Resonance Spectroscopy in Gliomas with Rare IDH Mutations: Making Sense of “False-Positive” Cases
Natsumeda, M., Igarashi, H., Gabdulkhaev, R., Takahashi, H., Motohashi, K., Ogura, R., Watanabe, J., Tsukamoto, Y., Okamoto, K., Kakita, A., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11112129 · Cited by 7
Advances in molecular and imaging biomarkers in lower-grade gliomas
Pïcca, A., Bruno, F., Nichelli, L., Sanson, M., & Rudà, R. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2285472 · Cited by 7
Neuroimaging and Genetic Influence in Treating Brain Neoplasms
da Cruz, L. C. H., & Kimura, M. (2014) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2014.09.011 · Cited by 7
Evaluation of Magnetonanoparticles Conjugated with New Angiogenesis Peptides in Intracranial Glioma Tumors by MRI
de Oliveira, E. A., Lazović, J., Guo, L., Soto, H., Faintuch, B. L., Akhtari, M., & Pope, W. B. (2017) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-017-2443-2 · Cited by 7
Self-citation
Isocitrate Dehydrogenase Mutations in Human Cancers: Physiopathologic Mechanisms and Therapeutic Targeting
malignancy, A. I. A. H. H., mutations, C. B. T. A. O. V. S. G. A. A. O. I. M. C. A. A. V. S. O. M. S. C. O. I. T. L. 2. D. H. L. T. T. I. O. T. B. T. O. G., (HPCs), W. C. T. S. D. O. T. L. P. T. C. I. M. C. A. S. A. T. H. S. C. (. A. P. C., in, S. A. T. M., of, T. L., in, O. T. M., HPCs, R. T. K. T. C. I. M. P. S.-R. A. B. T. D. O., involving, S. A. T. T. F., & involving, O. T. T. F. (2016) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2016.00019 · Cited by 8
Imaging in low-grade glioma: a guide for neurologists
Larsen, J., Hoggard, N., & McKevitt, F. M. (2017) · Practical Neurology · doi:10.1136/practneurol-2017-001686 · Cited by 7
Monitoring response to a clinically relevant IDH inhibitor in glioma—Hyperpolarized 13C magnetic resonance spectroscopy approaches
Hong, D., Kim, Y., Mushti, C., Minami, N., Wu, J., Cherukuri, M. K., Swenson, R. E., Vigneron, D. B., & Ronen, S. M. (2023) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdad143 · Cited by 6
The diagnostic efficiency of integration of 2HG MRS and IVIM versus individual parameters for predicting IDH mutation status in gliomas in clinical scenarios: A retrospective study
Yu, M., Ge, Y., Wang, Z., Zhang, Y., Hou, X., Chen, H., Chen, X., Ji, N., Li, X., & Shen, H. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04609-2 · Cited by 6
Genetics and imaging of oligodendroglial tumors
Ellenbogen, J. R., Walker, C. A., & Jenkinson, M. D. (2015) · CNS Oncology · doi:10.2217/cns.15.37 · Cited by 6
Interrogating IDH Mutation in Brain Tumor
Hu, J., Salzillo, T. C., Sailasuta, N., Lang, F. F., & Bhattacharya, P. K. (2017) · Topics in Magnetic Resonance Imaging · doi:10.1097/rmr.0000000000000113 · Cited by 6
Clinical applications of in vivo magnetic resonance spectroscopy in oncology
Payne, G. S. (2018) · Physics in Medicine and Biology · doi:10.1088/1361-6560/aae61e · Cited by 6
Current and future tools for determination and monitoring of isocitrate dehydrogenase status in gliomas
Pïcca, A., Stefano, A. L. D., & Sanson, M. (2018) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000617 · Cited by 6
In vivo characterization of physiological and metabolic changes related to isocitrate dehydrogenase 1 mutation expcression by multiparametric MRI and MRS in a rat model with orthotopically grafted human‐derived glioblastoma cell lines
Clément, A., Doyen, M., Fauvelle, F., Hossu, G., Chen, B., Barberi‐Heyob, M., Hirtz, A., Stupar, V., Lamiral, Z., Pouget, C., et al. (2021) · NMR in Biomedicine · doi:10.1002/nbm.4490 · Cited by 8
Association between accumulation of 2-hydroxyglutarate detected by MR spectroscopy and preoperative seizure in IDH-mutant glioma
Nagashima, H., Tanaka, K., Yamanishi, S., Hashiguchi, M., Iwahashi, H., Uno, T., Somiya, Y., Komatsu, M., Itoh, T., Sasaki, R., et al. (2024) · Journal of neurosurgery · doi:10.3171/2024.6.jns24166 · Cited by 6
Using radiomics based on multicenter magnetic resonance images to predict isocitrate dehydrogenase mutation status of gliomas
Liu, Y., Zheng, Z., Wang, Z., Qian, X., Yao, Z., Cheng, C., Zhou, Z., Gao, F., & Dai, Y. (2023) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-22-836 · Cited by 6
Stereotactic image‑based histological analysis reveals a correlation between 11C‑methionine uptake and MGMT promoter methylation in non‑enhancing gliomas
Okita, Y., Shofuda, T., Kanematsu, D., Yoshioka, E., Kodama, Y., Mano, M., Kinoshita, M., Nonaka, M., Nakajima, S., Fujinaka, T., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.8866 · Cited by 5
Comparative Value of 2-Hydroxyglutarate–to–Lipid and Lactate Ratio versus 2-Hydroxyglutarate Concentration on MR Spectroscopic Images for Predicting Isocitrate Dehydrogenase Mutation Status in Gliomas
Suh, C. H., Kim, H. S., Park, J. E., Jung, S. C., Choi, C. G., Woo, D., Lee, H. B., & Kim, S. J. (2020) · Radiology Imaging Cancer · doi:10.1148/rycan.2020190083 · Cited by 5
Quantitative Analysis of Oncometabolite 2-Hydroxyglutarate
Yuan, B. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-51652-9_11 · Cited by 5
Classification of Brain Tumor IDH Status using MRI and Deep LearningPreprint
Nalawade, S. S., Murugesan, G. K., Vejdani‐Jahromi, M., Fisicaro, R. A., Yogananda, C. G. B., Wagner, B. C., Mickey, B., Maher, E. A., Pinho, M. C., Fei, B., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/757344 · Cited by 5
Reverse Engineering Glioma Radiomics to Conventional Neuroimaging
Kinoshita, M., Kanemura, Y., Narita, Y., & Kishima, H. (2021) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2021-0133 · Cited by 4
Emerging Concepts in Neuro-Oncology
Sciuscio, D., & Hegi, M. E. (2012) · Springer eBooks · doi:10.1007/978-0-85729-458-6 · Cited by 5
Robust detection of oncometabolic aberrations by 1H–13C heteronuclear single quantum correlation in intact biological specimens
Barekatain, Y., Yan, V. C., Arthur, K., Ackroyd, J. J., Khadka, S., de Groot, J., Huse, J. T., & Müller, F. L. (2020) · Communications Biology · doi:10.1038/s42003-020-1055-5 · Cited by 4
Imaging 2-hydroxyglutarate and other brain oncometabolites pertinent to critical genomic alterations in brain tumors
Thomas, T., Thakur, S. B., & Young, R. J. (2023) · BJR|Open · doi:10.1259/bjro.20210070 · Cited by 6
Magnetic Resonance Spectroscopy of 2‐Hydroxyglutarate and Glycine in Adult Subjects With Brainstem Gliomas
Tiwari, V., Ganji, S., An, Z., Pinho, M. C., Davis, L. T., McKnight, C. D., Berry, J. D., Mobley, B. C., Luo, L. Y., Mohler, A. C., et al. (2025) · NMR in Biomedicine · doi:10.1002/nbm.70153 · Cited by 5
Tailoring imaging probes for defining glioma invasive margins: Tracing the molecular footprints of cancer cells
Qian, H., Yang, M., Wang, P., Graça, L., Sun, H., & Li, C. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123779 · Cited by 5
Isocitrate Dehydrogenase Mutations in Cancer: From Bench to Bedside Applications
Fang, Y., Wang, X., Luo, K., Dakal, T. C., Bai, H., Xu, C., & Zhang, G. (2026) · MedComm · doi:10.1002/mco2.70732 · Cited by 5
Intraoperative Magnetic Resonance Imaging in Neurosurgery
Kent, T., & Jensen, R. L. (2014) · Contemporary Neurosurgery · doi:10.1097/01.cne.0000459700.08563.a8 · Cited by 3
The Correlation of In Vivo MR Spectroscopy and Ex Vivo 2-Hydroxyglutarate Concentration for the Prediction of Isocitrate Dehydrogenase Mutation Status in Diffuse Glioma
van Dijken, B. R. J., Jeltema, H., Kłos, J., van Laar, P. J., Enting, R. H., Maatman, R. G. H. J., Bijsterveld, K., den Dunnen, W. F. A., Dierckx, R. A. J. O., Sijens, P. E., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13172791 · Cited by 3
2-Hydroxyglutarate as an MR spectroscopic predictor of an IDH mutation in gliomas
Bauer, J., Raum, H. N., Kugel, H., Müther, M., Mannil, M., & Heindel, W. L. (2024) · RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren · doi:10.1055/a-2285-4923 · Cited by 3
Detecting IDH and TERTp mutations in diffuse gliomas using 1H-MRS with attention deep-shallow networks
Sacli-Bilmez, B., Baş, A., Danyeli, A. E., Yakicier, M. C., Pamir, M. N., Özduman, K., Di̇nçer, A., & Öztürk-Işık, E. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.109736 · Cited by 3
Diffuse Astrocytoma and Oligodendroglioma: An Integrated Diagnosis and Management
Florian, I. Ş., & Șușman, S. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.76205 · Cited by 3
Advances in Imaging Brain Cancer
Price, S. J., & Waldman, A. D. (2012) · Springer eBooks · doi:10.1007/978-0-85729-458-6_8 · Cited by 3
Imaging Markers of Isocitrate Dehydrogenase-1 Mutations in Gliomas
Price, S. J. (2015) · Neurosurgery · doi:10.1227/neu.0000000000000812 · Cited by 3
A Deep Learning Approach for Placing Magnetic Resonance Spectroscopy Voxels in Brain Tumors
Lee, S., Branzoli, F., Nguyen, T., Andronesi, O. C., Lin, A. P., Liserre, R., Melkus, G., Chen, C. C., Marjańska, M., & Bolan, P. J. (2024) · Lecture notes in computer science · doi:10.1007/978-3-031-72384-1_51 · Cited by 2
Apparent diffusion coefficient predicts MGMT status in adult-type diffuse gliomas and is correlated with Ki-67 proliferation index
Zhu, F.-Y., Zhuo, L.-Y., Wang, T.-D., & Wang, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1609562 · Cited by 2
Advances in the management of patients with IDH-mutant glioma
Rossi, J., Pïcca, A., Santonocito, O. S., Schembari, S., Testaverde, L., Sanson, M., Berzero, G., & Stefano, A. L. D. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf391 · Cited by 5
Magnetic Resonance Spectroscopy of Cystathionine and 2‐Hydroxyglutarate in Brain Tumors
Choi, C., Huynh, M., Kovács, Z. Z., Behof, W. J., Pham, W. N., Ganji, S., An, Z., Patel, T., Maher, E. A., Berry, J. D., et al. (2025) · NMR in Biomedicine · doi:10.1002/nbm.70181 · Cited by 2
1H-NMR based metabolic study of MMTV-PyMT mice along with pathological progress to screen biomarkers for the early diagnosis of breast cancer
Liu, Y., Qi, C., Zheng, L., Li, J., Wang, L., & Yang, Y. (2021) · Molecular Omics · doi:10.1039/d1mo00387a · Cited by 2
Advanced multiparametric MRI-based scoring for isocitrate dehydrogenase mutation prediction of gliomas
Hosur, B., Ahuja, C. K., Singla, N., Gupta, K., & Singh, P. (2022) · Polish Journal of Radiology · doi:10.5114/pjr.2022.121549 · Cited by 2
Magnetic Resonance Spectroscopy: Clinical Applications
Horská, A., Berrington, A., Barker, P. B., & Tkáč, I. (2023) · Springer eBooks · doi:10.1007/978-3-031-10909-6_10 · Cited by 2
Neuroimaging of Brain Tumors in the Era of Radiogenomics
Batchala, P. P., Muttikkal, T. J. E., Donahue, J., Lopes, M. B. S., Williams, E. S., Tustison, N. J., & Patel, S. H. (2023) · Springer eBooks · doi:10.1007/978-3-031-10909-6_54 · Cited by 2
Integration of amide proton transfer-weighted imaging and methionine positron emission tomography histogram parameters enhances the prediction of isocitrate dehydrogenase mutations in adult diffuse gliomas
Kusunoki, M., Isoda, T., Yamashita, K., Kitamura, Y., Kikuchi, K., Sando, M., Baba, S., Kuga, D., Fujioka, Y., Narutomi, F., et al. (2025) · EJNMMI Reports · doi:10.1186/s41824-025-00248-6 · Cited by 2
CEST, pH, and Glucose Imaging as Markers for Hypoxia and Malignant Transformation
Paech, D., & Radbruch, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-27359-0_10 · Cited by 2
From K-space to Nucleotide
Elshafeey, N. A., Hassan, I. S. A., Zinn, P. O., & Colen, R. R. (2017) · Topics in Magnetic Resonance Imaging · doi:10.1097/rmr.0000000000000114 · Cited by 2
Accuracy of 1H magnetic resonance spectroscopy for quantification of 2-hydroxyglutarate using linear combination and J-difference editing at 9.4 T
Neuberger, U., Kickingereder, P., Helluy, X., Fischer, M. D., Bendszus, M., & Heiland, S. (2017) · Zeitschrift für Medizinische Physik · doi:10.1016/j.zemedi.2017.04.002 · Cited by 2
Pineal Gland Tumor Microenvironment
Choque‐Velasquez, J., Baluszek, S., Colasanti, R., Muhammad, S., & Hernesniemi, J. A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-59038-3_8 · Cited by 2
Radiological Prediction of Isocitrate Dehydrogenase (IDH) Mutational Status and Pathological Verification for Lower-Grade Astrocytomas
Yano, H., Ikegame, Y., Miwa, K., Nakayama, N., Maruyama, T., Ikuta, S., Yokoyama, K., Muragaki, Y., Iwama, T., & Shinoda, J. (2022) · Cureus · doi:10.7759/cureus.27157 · Cited by 3
Updates in the Neuoroimaging and WHO Classification of Primary CNS Gliomas
Colip, C. G., Öztek, M. A., Lo, S. S.-M., Yuh, W., & Fink, J. R. (2019) · Topics in Magnetic Resonance Imaging · doi:10.1097/rmr.0000000000000195 · Cited by 2
Review of WHO 2016 Changes to Classification of Gliomas; Incorporation of Molecular Markers
Johnson, D. R., Giannini, C., & Kaufmann, T. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-27359-0_8 · Cited by 2
Characterizing Brain Tumors by MRS
Howe, F. A., & Peet, A. C. (2016) · Encyclopedia of Magnetic Resonance · doi:10.1002/9780470034590.emrstm1425 · Cited by 2
Simultaneous brain tumor segmentation and molecular profiling using deep learning and T2w magnetic resonance images
Yogananda, C. G. B., Shah, B., Yu, F. F., Nalawade, S. S., Holcomb, J. M., Reddy, D. D., Wagner, B., Pinho, M. C., Mickey, B., Patel, T., et al. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91171-9.00005-3 · Cited by 1
Stereochemistry and Charged State Influence Effector Outcomes of d -2-Hydroxyglutarate Dehydrogenase Ligands
Quaye, J. A., & Gadda, G. (2025) · Biochemistry · doi:10.1021/acs.biochem.5c00408 · Cited by 1
Imaging biomarkers for detecting IDH mutations and monitoring response to novel targeted therapies: Current insights and future perspectives
Rajan, A., Castro, F. R., de Godoy, L. L., Hanaoka, M. M., Türk, S., Desiderio, L. M., Stupp, R., Suyash, M., & Chawla, S. (2026) · Neuro-Oncology · doi:10.1093/neuonc/noag028 · Cited by 1
Imaging the hallmarks of cancer
Grimm, J., Kiessling, F. M., Brindle, K. M., Hanahan, D., Jain, S. K., Lambin, P., Lammers, T., Li, K. C., de Vries, I. J., Weber, W., et al. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00950-y · Cited by 2
Gliomas phenocopy an inborn error of metabolism to drive neuronal activity and tumor growth
Abdullah, K. G., Miki, K., Edgar, C. K., Wu, S. A., Xiao, Y., Huang, Y.-T., Drexler, R., Krishna, S., Puliyappadamba, V. T., Tay, L. W. R., et al. (2026) · Cell · doi:10.1016/j.cell.2026.08.037 · Cited by 2
Isocitrate Dehydrogenase (IDH) Mutation in Gliomas
Chesnelong, C. (2015) · Springer eBooks · doi:10.1007/978-3-319-15811-2_25 · Cited by 1
Interdisziplinäre Neuroonkologie
Tabatabai, G., Hattingen, E., Schlegel, J., Stummer, W., & Schlegel, U. S. (2014) · Der Nervenarzt · doi:10.1007/s00115-014-4041-7 · Cited by 1
Background on Imaging Structural Imaging
Himes, N. C., & Young, G. S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800870-6.00002-9 · Cited by 1
Neuroimaging in patients with high-grade gliomas
Galldiks, N. (2018) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.18.03102-3 · Cited by 1
Investigation of histological heterogeneity based on the discrepancy between the hyperintense area on T2-weighted images and the accumulation area on 11C-methionine PET in minimally enhancing glioma
Ideguchi, M., Nishizaki, T., Ikeda, N., Fujii, N., Ohno, M., Shimabukuro, T., Kimura, T., Ikeda, E., & Suga, K. (2021) · Interdisciplinary Neurosurgery · doi:10.1016/j.inat.2021.101364 · Cited by 1
Neuro-oncology
Fink, K., & Rushing, E. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-03283-8_8 · Cited by 1
The role of radiogenomics
Puig, J., López‐Rueda, A., Oleaga, L., Gimeno, A., & Saba, L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99873-4.00005-0 · Cited by 1
Diagnostic and Theranostic Opportunities in Neuro-Oncology
Ritter, Z., Oeltzschner, G., Sólnes, L. B., Liu, G., & Kamson, D. O. (2024) · Advances in Oncology · doi:10.1016/j.yao.2024.01.001 · Cited by 1
Astrocytic and Oligodendroglial Tumors
Brat, D. J., & Perry, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-44941-0.00006-0 · Cited by 1
MRS for D-2HG Detection in IDH-Mutant Glioma
Andronesi, O. C., Batchelor, T. T., & Cahill, D. P. (2019) · Springer eBooks · doi:10.1007/978-3-030-27359-0_11 · Cited by 1
Pathology, Epidemiology, and WHO Classification of Brain Tumors
Yapıcıer, Ö. (2020) · Springer eBooks · doi:10.1007/978-3-030-23273-3_1 · Cited by 1
Maffucci Syndrome Complicated by Giant Chondrosarcoma in the Left Ankle with an IDH1 R132C Mutation: Case ReportPreprint
Lv, H., Jiang, H., Zhang, M., Luo, H., Hong, Z., Yang, H., Xu, W., Shen, B., & Zhu, R.-T. (2021) · Research Square · doi:10.21203/rs.3.rs-771590/v1 · Cited by 1
Desenvolvimento de radiotraçadores angiogênicos para diagnóstico de glioma: estudo em modelo animal
de Oliveira, E. A. (2014) · doi:10.11606/t.85.2014.tde-02122014-143353
Studies on the Roles of PDGFRA and EGFR in the Classification and Identification of Therapeutic Targets for Human Gliomas
Dong-feng, C. (2013) · Lund University Publications (Lund University)
Future Methods in Tumor Imaging
Pilatus, U., & Hattingen, E. (2015) · Medical radiology · doi:10.1007/174_2015_1055
Application of Volumetric Analysis to Glioblastomas: a Correlation Study on the Status of the Isocitrate Dehydrogenase Mutation
Bae, S. Y., Park, C., Kim, T. M., Park, S., Kim, I. H., & Choi, S. H. (2015) · Investigative Magnetic Resonance Imaging · doi:10.13104/imri.2015.19.4.218
Molecular Imaging of Diffuse Low Grade Glioma
Pope, W. B., & Spitler, K. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-55466-2_10
Self-citation
WHO-Klassifikation der Hirntumoren 2016: radiologisch relevante Neuerungen
Johnson, D. R., Guerin, J. B., Giannini, C., Morris, J. M., Eckel, L. J., & Kaufmann, T. J. (2018) · Neuroradiologie Scan · doi:10.1055/a-0638-3400
Radiogenomics of Oncology
Chiang, J., & Jamshidi, N. (2019) · Advances in Clinical Radiology · doi:10.1016/j.yacr.2019.04.012
Advances in Noninvasive Neurodiagnostics
Urgun, K., Ball, B. Z., & Hsu, F. P. K. (2020) · World Neurosurgery · doi:10.1016/j.wneu.2020.03.015
Magnetic Resonance for non-invasive evaluation of preclinical models of human brain tumors
Hamans, B. C. (2015) · Radboud Repository (Radboud University)
Does Blood-Brain Barrier Disruption Define the Glioma Extracellular Metabolome?Preprint
Riviere-Cazaux, C., Carlstrom, L. P., Rajani, K. R., Munoz-Casabella, A., Rahman, M., Loron, A. G., Brown, D. A., Miller, K. J., White, J. J., Himes, B. T., et al. (2021) · medRxiv · doi:10.1101/2021.08.24.21262320
La adquisición de la propiedad por subasta en los procesos de ejecución: Comentario a la Sentencia del Tribunal Supremo (Sala 1ª) de 24 de junio de 1997
Castro, M. N. (1998) · Revista chilena de derecho privado
Imaging Genomics
Kersch, C. N., & Barajas, R. (2019) · Springer eBooks · doi:10.1007/978-3-030-27359-0_14
Der diagnostische Stellenwert der Isocitrat-Dehydrogenase-Mutationen beim Chondrosarkom
Juratli, T. A. (2022) · Osteologie/Osteology · doi:10.1055/a-1725-2083
Cerebral Neoplasms
Fatterpekar, G. M., & Knopp, E. (2020) · IDKD Springer series · doi:10.1007/978-3-030-38490-6_4
Magnetic resonance spectroscopy and methionine positron emission tomography analysis for patients with lower-grade astrocytoma with marked invasivenessPreprint
Yano, H., Ikegame, Y., Miwa, K., Owashi, E., Nakayama, N., Maruyama, T., Matsunaga, K., Ohe, N., Takei, H., Ikuta, S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1643519/v1
Systems Of Active Immune Suppression As Integral Malignant Transformation In Infiltrating Glioma Cells
Agius, L. M. (2021) · Journal of Cancer Therapy and Research · doi:10.52793/jctr.2021.1(1)-03
The Descriptive and Analytical Epidemiology of Glioblastoma Worldwide: an Informative Science ReviewPreprint
Negrão, C. V. Z. D. V., Telles, J. P. M., Guirado, V. M. D. P., Menezes, L. V., Léo, P., Moraes, O., Figueiredo‬‬‬, E. G., Dias, S. M. G., & Cerize, N. N. P. (2023) · doi:10.31219/osf.io/89c3r

Authors: Pope, W. B., Prins, R. M., Albert Thomas, M., Nagarajan, R., Yen, K. E., Bittinger, M. A., Salamon, N., Chou, A. P., Yong, W. H., Soto, H., Wilson, N., Driggers, E., Jang, H. G., Su, S. M., Schenkein, D. P., Lai, A., Cloughesy, T. F., Kornblum, H. I., Wu, H., Fantin, V. R., & Liau, L. M.
Affiliations: University of California, Los Angeles (US)
Agios Pharmaceuticals (United States) (US)
Corresponding author: Liau, Linda M.
ORCID: Pope, Whitney B.
Prins, Robert M.
Nagarajan, Rajakumar
Yen, Katharine E.
Salamon, Noriko
Yong, William H.
Wilson, Neil
Jang, Hyun G.
Lai, Albert
Cloughesy, Timothy F.
Kornblum, Harley I.
Wu, Hong
Fantin, Valeria R.
Liau, Linda M.
Venue: Journal of Neuro-Oncology
Publisher: Springer Science and Business Media LLC
Published: 2011-10-21
Volume: 107
Issue: 1
Pages: 197-205
ISSN: 0167-594X (ISSN-L)
1573-7373
DOI: 10.1007/s11060-011-0737-8
PMC: PMC3650613
OpenAlex: W2083820071
Cited by: 318
References: 32
Citations by year: 2026: 14 · 2025: 8 · 2024: 12 · 2023: 22 · 2022: 15 · 2021: 23 · 2020: 26 · 2019: 27 · 2018: 27 · 2017: 32 · 2016: 29 · 2015: 27 · 2014: 24 · 2013: 17 · 2012: 13
FWCI: 8.64
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Journal of Neuro-Oncology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (UL1TR000124)
National Cancer Institute (R01CA121131, R01CA123396, K01CA111402, R01CA112358)
National Institute of Neurological Disorders and Stroke (R01NS052563)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced MRI Techniques and Applications
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
Keywords: 2-hydroxyglutarate, IDH1 mutation, glioma, oncometabolites, magnetic resonance spectroscopy, non-invasive cancer detection, choline, glutathione, Ki-67 proliferation index, tumor metabolites, biomarkers
MeSH terms: Adult, Aged, Aged, 80 and over, Brain Neoplasms, Chromatography, Liquid, DNA, Neoplasm, Female, Follow-Up Studies, Glioma, Glutarates, Humans, Isocitrate Dehydrogenase, Magnetic Resonance Imaging, Male, Middle Aged, Mutation, Magnetic Resonance Spectroscopy, Prognosis, Prospective Studies, Mass Spectrometry, Biomarkers, Tumor, Polymerase Chain Reaction, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks